Immuneering

IMRX

Market cap $435M

Immuneering (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The mean of analysts' price targets for Immuneering (IMRX) points to a 126.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Piper Sandler 37th Annual Healthcare Conference in New York City. Participating will be Ben Zeskind, Co-founder and Chief Executive Officer, Igor Matushansky M.D.

Immuneering Corporation ( IMRX ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Benjamin Zeskind - Co-Founder, President, CEO & Director Mallory Morales - Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer Conference Call Participants Laurence Watts - Gilmartin Group LLC Allyson Ocean Gregory Botta Jay Olson - Oppenheimer & Co. Inc., Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Ami Fadia - Needham & Company, LLC, Research Division Presentation Operator Welcome to the Immuneering Conference Call to discuss the Company's Third Quarter 2025 Financial Results and share investigator-presented clinical case studies in pancreatic patients. [Operator Instructions] I would now like to turn the call conference over to Laurence Watts of New Street Investor Relations.

- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP -

Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.

- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday, November 12, 2025, at 4:30 pm ET - NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that the company will report third quarter 2025 financial results and trial investigators will provide case studies from first-line pancreatic cancer patients treated in the company's Phase 2a study of atebimetinib in combination with FOLFIRINOX, on Wednesday, November 12, 2025, after the close of market. Immuneering will host a conference call and webcast at 1:30 pm PT / 4:30 pm ET on the same day.

Immuneering Corporation - Special Call Company Participants Benjamin Zeskind - Co-Founder, President, CEO & Director Conference Call Participants Laurence Watts Jay Olson - Oppenheimer & Co. Inc., Research Division Poorna Kannan - Needham & Company, LLC, Research Division Presentation Operator Hello, and welcome to the Immuneering conference call to discuss the positive 9-month update announced last week from the company's ongoing Phase IIa trial of atebemetinib and first-line pancreatic cancer patients. [Operator Instructions] As a reminder, this call is being recorded today, Monday, September 29, 2025.

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up.

Immuneering Corporation is upgraded to a Strong Buy due to positive phase 2a data for atebimetinib in 1st-line RAS-mutant pancreatic cancer. IMRX's atebimetinib plus mGnP achieved superior 9-month overall survival (86%) and progression-free survival (53%) compared to standard of care. Key catalysts include expected FDA feedback in Q4 2025, potential phase 3 initiation by end of 2025, and expansion into other solid tumors and NSCLC.